-
Bente D, Gren J, Strong JE, Feldmann H. 2009. Disease modeling for ebola and marburg viruses. Dis Model Mech, 2: 12-17.
-
Cross RW, Fenton KA, Geisbert JB, Mire CE, Geisbert TW. 2015. Modeling the disease course of zaire ebolavirus infection in the outbred guinea pig. J Infect Dis, 212 Suppl 2: S305-S315.
-
Feldmann H, Sprecher A, Geisbert TW. 2020. Ebola. N Engl J Med, 382: 1832-1842.
-
Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V, Klenk HD, Feldmann H, Stroher U. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol, 78: 5458-5465.
-
Geisbert TW, Strong JE, Feldmann H. 2015. Considerations in the use of nonhuman primate models of ebola virus and marburg virus infection. J Infect Dis, 212 Suppl 2: S91-S97.
-
Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM. 2013. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol, 87: 4952-4964.
-
Jacob ST, Crozier I, Fischer WA, 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH. 2020. Ebola virus disease. Nat Rev Dis Primers, 6: 13.
-
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon J, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamze B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG, Team PS. 2023. Immunogenicity and vaccine shedding after 1 or 2 doses of rvzvdeltag-zebov-gp ebola vaccine (ervebo(r)): Results from a phase 2, randomized, placebo-controlled trial in children and adults. Clin Infect Dis, https://doi.org/10.1093/cid/ciad693.
-
Lee HN, McWilliams IL, Lewkowicz AP, Engel K, Ireland DDC, Kelley-Baker L, Thacker S, Piccardo P, Manangeeswaran M, Verthelyi D. 2021. Characterization of the therapeutic effect of antibodies targeting the ebola glycoprotein using a novel bsl2-compliant rvsvdeltag-ebov-gp infection model. Emerg Microbes Infect, 10: 2076-2089.
-
Marzi A, Kercher L, Marceau J, York A, Callsion J, Gardner DJ, Geisbert TW, Feldmann H. 2015. Stat1-deficient mice are not an appropriate model for efficacy testing of recombinant vesicular stomatitis virus-based filovirus vaccines. J Infect Dis, 212 Suppl 2: S404-S409.
-
McWilliams IL, Kielczewski JL, Ireland DDC, Sykes JS, Lewkowicz AP, Konduru K, Xu BC, Chan CC, Caspi RR, Manangeeswaran M, Verthelyi D. 2019. Pseudovirus rvsvdeltag-zebov-gp infects neurons in retina and cns, causing apoptosis and neurodegeneration in neonatal mice. Cell Rep, 26: 1718-1726 e1714.
-
Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE, Jr., Andersen KG, Saphire EO, Ward AB. 2016. Structures of ebola virus gp and sgp in complex with therapeutic antibodies. Nat Microbiol, 1: 16128.
-
Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. 2000. Recombinant rna replicons derived from attenuated venezuelan equine encephalitis virus protect guinea pigs and mice from ebola hemorrhagic fever virus. Vaccine, 19: 142-153.
-
Raymond J, Bradfute S, Bray M. 2011. Filovirus infection of stat-1 knockout mice. J Infect Dis, 204 Suppl 3: S986-S990.
-
Saito T, Maruyama J, Nagata N, Isono M, Okuya K, Takadate Y, Kida Y, Miyamoto H, Mori-Kajihara A, Hattori T, Furuyama W, Ogawa S, Iida S, Takada A. 2020. A surrogate animal model for screening of ebola and marburg glycoprotein-targeting drugs using pseudotyped vesicular stomatitis viruses. Viruses, 12, 923.
DownLoad: